The National Institutes of Health (NIH) National Cancer Institute has granted $124,000 to Aastrom Biosciences, Inc. to develop an immunotherapeutic treatment of malignant melanoma using AastromReplicell System cell production technology.
Upadacitinib Outperforms Dupilumab in Primary and Secondary End Points in Head-to-Head AD Study
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment
Seemal Desai, MD, Responds to Study Suggesting Melanoma is Overdiagnosed in White Patients
ReV Up Your Vitiligo Treatment Strategies
Facial Skin Cancer Surgery Yields Low and Improved Scores For Perceived Stigmatization, Body Image Concerns, and Psychosocial Distress
US Central and European Commands Should Revisit Disallowance of Systemic Treatments for Deployed Individuals With Psoriasis, Eczema, Paper Argues